These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24173967)

  • 1. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
    Strickler JH; McCall S; Nixon AB; Brady JC; Pang H; Rushing C; Cohn A; Starodub A; Arrowood C; Haley S; Meadows KL; Morse MA; Uronis HE; Blobe GC; Hsu SD; Zafar SY; Hurwitz HI
    Invest New Drugs; 2014 Apr; 32(2):330-9. PubMed ID: 24173967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
    Rangwala F; Bendell JC; Kozloff MF; Arrowood CC; Dellinger A; Meadows J; Tourt-Uhlig S; Murphy J; Meadows KL; Starr A; Broderick S; Brady JC; Cushman SM; Morse MA; Uronis HE; Hsu SD; Zafar SY; Wallace J; Starodub AN; Strickler JH; Pang H; Nixon AB; Hurwitz HI
    Invest New Drugs; 2014 Aug; 32(4):700-9. PubMed ID: 24711126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
    Cabebe EC; Fisher GA; Sikic BI
    Invest New Drugs; 2012 Jun; 30(3):1082-7. PubMed ID: 21404105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
    Hoehler T; von Wichert G; Schimanski C; Kanzler S; Moehler MH; Hinke A; Seufferlein T; Siebler J; Hochhaus A; Arnold D; Hallek M; Hofheinz R; Hacker UT
    Br J Cancer; 2013 Sep; 109(6):1408-13. PubMed ID: 23963139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
    Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
    Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
    Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
    Jackson CG; Sharples K; Thompson PI; O'Donnell A; Robinson BA; Perez DJ; Adams J; Isaacs R; Deva S; Hinder VA; Findlay MP
    BMC Cancer; 2014 Oct; 14():737. PubMed ID: 25274181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
    Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
    Liu Y; Starr MD; Bulusu A; Pang H; Wong NS; Honeycutt W; Amara A; Hurwitz HI; Nixon AB
    Cancer Med; 2013 Apr; 2(2):234-42. PubMed ID: 23634291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
    Dotan E; Meropol NJ; Burtness B; Denlinger CS; Lee J; Mintzer D; Zhu F; Ruth K; Tuttle H; Sylvester J; Cohen SJ
    J Gastrointest Cancer; 2012 Dec; 43(4):562-9. PubMed ID: 22294255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
    Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
    Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
    Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
    Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
    Hurwitz H; Mitchell EP; Cartwright T; Kwok A; Hu S; McKenna E; Patt YZ
    Oncologist; 2012; 17(7):937-46. PubMed ID: 22622147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Vamvakas L; Matikas A; Karampeazis A; Hatzidaki D; Kakolyris S; Christophylakis C; Boukovinas I; Polyzos A; Georgoulias V; Souglakos J
    BMC Cancer; 2014 Apr; 14():277. PubMed ID: 24755296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
    Wong NS; Fernando NH; Bendell JC; Morse MA; Blobe GC; Honeycutt W; Pang H; Hurwitz HI
    Clin Colorectal Cancer; 2011 Sep; 10(3):210-6. PubMed ID: 21855046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
    Czito BG; Bendell JC; Willett CG; Morse MA; Blobe GC; Tyler DS; Thomas J; Ludwig KA; Mantyh CR; Ashton J; Yu D; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):472-8. PubMed ID: 17498568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
    Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
    Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
    Miyamae Y; Takahashi K; Igarashi T; Tanaka K; Takahashi N; Hirai K; Tsukagoshi H; Ogawa H; Yoshinari D; Sunose Y; Takeyoshi I
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):737-41. PubMed ID: 25129085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
    Brady J; Corrie P; Chau I; Digumarti R; Adams LM; Botbyl J; Laubscher KH; Midgley RS; Mallath M
    Invest New Drugs; 2013 Oct; 31(5):1228-35. PubMed ID: 23456563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.